Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024)

Aytu Biopharma (AYTU) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 557000.0 as the latest value for Q2 2024.

Quarterly Liabilities from Discontinued Operations changed N/A to 557000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 557000.0 through Jun 2024, changed N/A year-over-year, with the annual reading at 557000.0 for FY2024, N/A changed from the prior year.
Liabilities from Discontinued Operations for Q2 2024 was 557000.0 at Aytu Biopharma.
The five-year high for Liabilities from Discontinued Operations was 557000.0 in Q2 2024, with the low at 557000.0 in Q2 2024.